Document is current
Any future updates will be listed below
-
Authors
Nielsen, Sebastian W. http://orcid.org/0000-0003-3584-9154
Hasselsteen, Simone Dyring http://orcid.org/0000-0002-6014-2487
Dominiak, Helena Sylow Heilmann http://orcid.org/0000-0001-8543-1907
Labudovic, Dejan http://orcid.org/0000-0001-5652-9980
Reiter, Lars http://orcid.org/0000-0002-7224-929X
Dalton, Susanne Oksbjerg http://orcid.org/0000-0002-5485-2730
Herrstedt, Jørn http://orcid.org/0000-0002-8844-6546
-
Funding
Funding for this research was provided by:
NEYE Foundation
- License Information
-
More Information
Article History
Received: 12 April 2022
Accepted: 3 August 2022
First Online: 6 August 2022
Declarations
:
: The trial adhered to the Declaration of Helsinki and standards of Good Clinical Practice (GCP). The Danish Medicines Agency and the Ethical Committee approved the trial (EudraCT: 2020–002681-14, Protocol ID: SJ-846). GCP monitoring was conducted by the Danish GCP Units, Copenhagen Department. Data was handled in compliance with EU General Data Protection Regulation and the Danish Data Protection Act.
: All patients provided written consent.
: N/A.
: The authors declare no competing interests.
